Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jazz Pharmaceuticals, Inc. on June 4, 2010, covering events occurring on June 4, 2010, and the Annual Meeting of Stockholders held on June 7, 2010. The filing details corporate governance changes, specifically the election of a new director and the results of shareholder votes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased the total number of authorized directors to thirteen (13).
- New Director Election: Paul L. Berns was elected to the Board effective June 4, 2010. He serves in the class expiring at the 2011 Annual Meeting.
- Compensation Arrangements: Mr. Berns received a $30,000 annual retainer and an initial stock option to purchase 30,000 shares of Common Stock. He is eligible for additional retainers if appointed as a committee chair and participates in the Directors Deferred Compensation Plan.
- Annual Meeting Results: Shareholders approved the election of four Class III directors (Bruce C. Cozadd, Michael W. Michelson, Kenneth W. O'Keefe, and Alan M. Sebulsky) and ratified the selection of Ernst & Young LLP as the independent auditor.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on business strategy, or specific risk factors. The document notes the execution of a standard indemnity agreement for Mr. Berns, protecting him against certain legal expenses incurred due to his position as a director.
Investor Verification Checklist
- Verify the vesting schedule of the 30,000 initial stock options granted to Paul L. Berns (one-third on first anniversary, remainder over 24 months).
- Confirm the total number of shares outstanding (31,538,547) and the percentage of shares voted at the Annual Meeting (28,227,922 shares present).
- Review the specific vote counts for the Class III director elections to assess shareholder support levels.
- Check subsequent filings for any committee appointments for Mr. Berns, which would trigger supplemental annual retainers.